Trevi Therapeutics announced the pricing of its underwritten public offering of 17,400,000 shares of its common stock at $5.75 per share. This offering is expected to generate total proceeds of $100 million before deducting underwriting discounts and commissions.
The company also granted the underwriters a 30-day option to purchase up to an additional 2,610,000 shares of common stock at the public offering price. The offering is anticipated to close around June 5, 2025, subject to customary closing conditions.
This significant capital raise is intended to provide funding for the continued development of Haduvio, particularly as the company plans for pivotal Phase 3 trials following recent positive clinical data.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.